Biomarker-Guided Development of DNA Repair Inhibitors

Anti-cancer drugs targeting the DNA damage response (DDR) exploit genetic or functional defects in this pathway through synthetic lethal mechanisms. For example, defects in homologous recombination (HR) repair arise in cancer cells through inherited or acquired mutations in BRCA1, BRCA2, or other ge...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Molecular cell Ročník 78; číslo 6; s. 1070
Hlavní autoři:	Cleary, James M, Aguirre, Andrew J, Shapiro, Geoffrey I, D'Andrea, Alan D
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 18.06.2020
Témata:	Animals Antineoplastic Agents - therapeutic use Biomarkers, Pharmacological DNA Damage - drug effects DNA End-Joining Repair - drug effects DNA Repair - drug effects DNA Repair - genetics DNA Repair - physiology Genes, BRCA1 - drug effects Homologous Recombination Humans Neoplasms - drug therapy Poly(ADP-ribose) Polymerase Inhibitors - pharmacology Poly(ADP-ribose) Polymerases - metabolism cell-cycle kinases DNA repair polymerase theta PARP inhibitor
ISSN:	1097-4164, 1097-4164
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	Anti-cancer drugs targeting the DNA damage response (DDR) exploit genetic or functional defects in this pathway through synthetic lethal mechanisms. For example, defects in homologous recombination (HR) repair arise in cancer cells through inherited or acquired mutations in BRCA1, BRCA2, or other genes in the Fanconi anemia/BRCA pathway, and these tumors have been shown to be particularly sensitive to inhibitors of the base excision repair (BER) protein poly (ADP-ribose) polymerase (PARP). Recent work has identified additional genomic and functional assays of DNA repair that provide new predictive and pharmacodynamic biomarkers for these targeted therapies. Here, we examine the development of selective agents targeting DNA repair, including PARP inhibitors; inhibitors of the DNA damage kinases ataxia-telangiectasia and Rad3 related (ATR), CHK1, WEE1, and ataxia-telangiectasia mutated (ATM); and inhibitors of classical non-homologous end joining (cNHEJ) and alternative end joining (Alt EJ). We also review the biomarkers that guide the use of these agents and current clinical trials with these therapies.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
ISSN:	1097-4164 1097-4164
DOI:	10.1016/j.molcel.2020.04.035